Typical mRNA (Drug Substance) Specifications
| Quality Attribute | Purpose / Rationale | Primary Method(s) | Orthogonal Method(s) | Acceptance Criteria |
|---|---|---|---|---|
| Appearance | Confirms absence of visible contaminants or precipitation; ensures bulk DS is suitable for downstream formulation. | Visual Inspection (Manual) | – | Clear, colorless solution, essentially free of visible particulates. |
| pH (potential of hydrogen) | Confirms bulk RNA solution is within stability range. | Potentiometric pH measurement | – | 6.5–7.6 (typical); product-specific range established based on stability profile |
| Osmolality | Ensures solution compatibility/stability. Product-specific; typically measured only when DS contains osmolytes (e.g., sucrose, trehalose) or is formulated at defined ionic strength. | Osmometry | – | Target ± Range (e.g., Target ± 30 mOsm/kg). Note: Only applicable if DS is stored in a final formulated buffer. |
| Identity | Confirms mRNA encodes the intended protein. | Sanger Sequencing RT-PCR Digital PCR (dPCR/ddPCR) | Next-Generation Sequencing (NGS) mRNA Sequence Mapping by LC-MS/MS | Matches reference sequence for defined regions; no unexpected variants above defined reporting threshold (e.g., ≥X% of reads) in coding sequence/critical elements. |
| mRNA Integrity / Size Heterogeneity | Confirms the presence and relative proportion of full-length mRNA and detects truncated or degraded species relevant to product quality, potency, and consistency. | Capillary Gel Electrophoresis (CGE) for Nucleic Acids | Ion-Pair Reverse Phase HPLC (IP-RP HPLC) | • % Full-length (main peak): ≥80–95% (typical) (Range depends on construct length, sequence complexity, and process capability)• Truncated species: No single impurity >X% (product-specific limit; typically <5% per species) |
| 5′ Capping Efficiency | Ensures translational efficiency and immune safety (reduces innate immune activation via RIG-I/MDA5). Confirms correct cap structure (Cap 0 vs. Cap 1). | 5′ Cap Structure Analysis by Enzymatic Digestion & Mass Spectrometry | Ion-Pair Reverse Phase HPLC (IP-RP HPLC) | Total capped species: ≥90–95% (product-specific)• Cap structure profile: Consistent with qualified reference standard - For enzymatic capping (e.g., CleanCap): ≥90% Cap 1 - For co-transcriptional capping: Cap 0/Cap 1 ratio per reference• Uncapped RNA: ≤5–10% (justified limit) |
| Poly(A) tail length, distribution, and heterogeneity | Determines mRNA stability, intracellular half-life, and translational efficiency. Ensures process consistency and product quality. | Nanopore sequencing Poly(A) Tail Analysis via LC-MS | Reverse Phase HPLC (RP-HPLC) | • Mean tail length: Within defined range relative to reference standard (e.g., target ± 10 nt; or specified range such as 100–120 nt)• Distribution profile: Consistent with qualified reference standard• Short tails (<30 nt): <X% (limits established during development)• Tail heterogeneity: Within process control limits |
| mRNA Concentration (Total) | Quantifies total nucleic acid content for formulation calculations and dose preparation | UV-Vis Spectrophotometry SoloVPE (slope spectroscopy) | Reverse Phase HPLC (RP-HPLC) | 90–110% of target concentration (e.g., 0.9–1.1 mg/mL for 1.0 mg/mL target) ; Established based on process capability and clinical dose requirements |
| Functional RNA Content | Confirms presence of reverse-transcribable, structurally intact mRNA. Provides orthogonal, transcript-specific measure of RNA content and quality. | RT-PCR Digital PCR (dPCR/ddPCR) | – | Comparable to qualified reference standard; Product-specific acceptance range established during development (e.g., 80–120% relative to reference standard). |
| dsRNA Impurity | dsRNA triggers innate immune responses (via TLR3, RIG-I, MDA5); must be minimized to ensure safety. | Double-stranded RNA (dsRNA) detection | – | • <100 pg dsRNA/µg RNA OR Below Limit of Detection (LOD)• Product-specific limit justified by safety data |
| Residual Plasmid DNA | Ensures plasmid DNA template clearance to meet regulatory safety requirements. | qPCR for Residual DNA Analysis Digital PCR (dPCR/ddPCR) | – | • ≤10 ng DNA/mg RNA (typical)• Product-specific limit based on maximum dose and regulatory guidance |
| Residual Protein (IVT enzymes) | Ensures clearance of IVT enzymes (RNA polymerase, nucleases, capping enzymes) and bacterial host cell proteins. | BCA Assay | – | < 100 ng/mg RNA. |
| Residual Process Impurities (NTPs, cap analogs, buffer components) | Ensures removal of unreacted nucleotides/reagents. | Anion-Exchange High-Performance Liquid Chromatography (AEX-HPLC) | UV-Vis Spectrophotometry | • Residual NTPs: <X mg/mg RNA• Cap analog: <Y%• Limits established during process validation (Product-specific; justified by process capability and toxicology assessment) |
| Endotoxin | Prevents pyrogenic reactions. | Bacterial Endotoxin Tests (BET) | – | • Must be below product-specific limit to enable DP compliance with pharmacopeial requirements (Typically ≤10 EU/mg or calculated based on maximum clinical dose and route of administration) |
| Bioburden: Pre-Sterilization Microbial Control (IPC) | Ensures microbial load in the bulk drug substance is acceptably low to support aseptic formulation and prevent downstream contamination. | Procedure: USP <61> Microbial Enumeration Tests | Rapid Microbiological Methods (RMMs) | Meets product-defined limit (e.g., ≤ 10 CFU/mL), justified by process capability and risk assessment. |
| Mycoplasma Contamination | Detects mycoplasma contamination. | Mycoplasma Detection | Digital PCR (dPCR/ddPCR) | Negative |